Health and Healthcare

Merck : MRK

All Merck Articles

1087 Articles

Jon C. Ogg | Feb 5, 2020 at 1:20 PM EST

Merck’s Spin-Off May Create Operational Risks for the Year Ahead

Merck finds itself in a position of being an acquirer of sorts at the same time it wants to spin…

Chris Lange | Feb 5, 2020 at 9:55 AM EST

Is Merck Stuck in the Slow Lane?

Merck reported fourth-quarter financial results before the markets opened on Wednesday that were essentially in line with expectations, yet shares…

Chris Lange | Feb 4, 2020 at 1:05 PM EST

What to Expect When Merck Reports Before the Opening Bell

Merck is scheduled to release its fourth-quarter financial results before the markets open on Wednesday. Analysts are looking for year-over-year…

Chris Lange | Feb 2, 2020 at 7:05 AM EST

Alphabet, Disney, Ford, Twitter, Uber and More Major Earnings Coming This Week

24/7 Wall St. has put together a preview of Disney, Ford, Merck, Uber and some of the other most anticipated…

Chris Lange | Jan 28, 2020 at 9:35 AM EST

Short Sellers Can’t Make Up Their Mind on Big Pharma

The January 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jan 13, 2020 at 9:40 AM EST

Short Sellers Shy Away From Big Pharma

The December 31 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Jan 6, 2020 at 12:45 PM EST

2020 Bull/Bear Outlook Sees the Dow Rising to 30,650 Before Year-End

Here is a review and preview of how the model for Dow Jones industrial average could point to a baseline…

Jon C. Ogg | Jan 2, 2020 at 4:51 PM EST

Is Pfizer Raising Drug Prices Too Much in 2020?

Ahead of election years, the cost and future of health care has become one of the top debates for better…

Chris Lange | Jan 2, 2020 at 10:25 AM EST

The Top Biopharma Events to Watch in 2020

Here, 24/7 Wall St. presents a calendar of a few of the biggest clinical trial and FDA updates to watch…

Chris Lange | Dec 26, 2019 at 8:55 AM EST

Big Pharma Short Sellers Get Selective

The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Dec 23, 2019 at 11:00 AM EST

The Top Biopharma Calendar Events to Watch Going Into 2020

Here, 24/7 Wall St. has included a calendar of a few of the biggest clinical trial and FDA updates to…

Chris Lange | Dec 20, 2019 at 11:45 AM EST

The First Ebola Vaccine Has Been Approved in the US

NewLink Genetics and Merck shares made handy gains on Friday after it was announced that the FDA has granted approval…

Jon C. Ogg | Dec 13, 2019 at 12:25 PM EST

Meet the Preliminary 2020 Dogs of the Dow

One theme that investors love in good times and in bad is dividend investing. One strategy that has been around…

Chris Lange | Dec 11, 2019 at 9:45 AM EST

Big Pharma Short Sellers Grow More Selective

The November 29 short interest data have been compared with the previous figures, and short interest moves in these selected…

Trey Thoelcke | Dec 11, 2019 at 7:10 AM EST

The 6 Most Shorted Dow Stocks

As of the most recently reported period, short sellers favored Apple, Microsoft and Intel above all other Dow stocks.

1 … 13 14 15 16 17 … 73

Merck : MRK

All Merck Articles

Merck’s Spin-Off May Create Operational Risks for the Year Ahead

Is Merck Stuck in the Slow Lane?

What to Expect When Merck Reports Before the Opening Bell

Alphabet, Disney, Ford, Twitter, Uber and More Major Earnings Coming This Week

Short Sellers Can’t Make Up Their Mind on Big Pharma

Short Sellers Shy Away From Big Pharma

2020 Bull/Bear Outlook Sees the Dow Rising to 30,650 Before Year-End

Is Pfizer Raising Drug Prices Too Much in 2020?

The Top Biopharma Events to Watch in 2020

Big Pharma Short Sellers Get Selective

The Top Biopharma Calendar Events to Watch Going Into 2020

The First Ebola Vaccine Has Been Approved in the US

Meet the Preliminary 2020 Dogs of the Dow

Big Pharma Short Sellers Grow More Selective

The 6 Most Shorted Dow Stocks

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America’s Debt Just Crossed a Level It Hasn’t Hit Since 1946, and Households Are Next in Line

‘Over My Dead Body’: Suze Orman to a Listener Who Wanted to Pay Off His Dying Father-in-Law’s $50,000 in Credit Card Debt

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America’s Debt Just Crossed a Level It Hasn’t Hit Since 1946, and Households Are Next in Line

Merck : MRK

All Merck Articles

Merck’s Spin-Off May Create Operational Risks for the Year Ahead

Is Merck Stuck in the Slow Lane?

What to Expect When Merck Reports Before the Opening Bell

Alphabet, Disney, Ford, Twitter, Uber and More Major Earnings Coming This Week

Short Sellers Can’t Make Up Their Mind on Big Pharma

Short Sellers Shy Away From Big Pharma

2020 Bull/Bear Outlook Sees the Dow Rising to 30,650 Before Year-End

Is Pfizer Raising Drug Prices Too Much in 2020?

The Top Biopharma Events to Watch in 2020

Big Pharma Short Sellers Get Selective

The Top Biopharma Calendar Events to Watch Going Into 2020

The First Ebola Vaccine Has Been Approved in the US

Meet the Preliminary 2020 Dogs of the Dow

Big Pharma Short Sellers Grow More Selective

The 6 Most Shorted Dow Stocks

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America’s Debt Just Crossed a Level It Hasn’t Hit Since 1946, and Households Are Next in Line

‘Over My Dead Body’: Suze Orman to a Listener Who Wanted to Pay Off His Dying Father-in-Law’s $50,000 in Credit Card Debt

Featured Reads

A 52-Year-Old With $1.2 Million in a 401(k) Can Access $40,000 Annually Penalty-Free at 57 Using This Strategy

America's Debt Just Crossed a Level It Hasn't Hit Since 1946, and Households Are Next in Line